Differentiated Thyroid Cancer Clinical Trial
Official title:
A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)
- To find out the gap between real-world clinical practice and guideline recommendations
in initial management of DTC patients
- To observe the characteristics of patients who achieved and did not achieve TSH target
value after one year follow-up
- To assess response to initial therapy in patients who undergo total or near-total
thyroidectomy and RAI remnant ablation after one year follow-up (according to an
modified dynamic risk stratification system)
- To observe the recurrence status after one year follow-up
Multi-center, prospective, registry study
2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or
high risk of recurrence will be recruited. Doctors can treat the patients based on disease
conditions. Investigators will record data which are related to study endpoints.
Primary endpoint(s):
1. Proportion of patients who underwent total/near-total thyroidectomy
2. Proportion of patients who were treated by 131I after undergoing total/near-total
thyroidectomy
3. Proportion of patients who achieved serum TSH target value
4. Proportion of patients who did not achieve serum TSH target value although they were
treated by TSH suppression therapy
Secondary endpoint(s):
1. Time to achieve serum TSH target value
2. Dosage of L-T4 for patients who achieved and did not achieve serum TSH target value
3. Dosage of L-T4 per kilogram of body weight for patients who achieved and did not
achieve serum TSH target value
4. Proportion of excellent response/Acceptable response/Biochemical incomplete
response/Structural incomplete response to initial management in patients who undergo
total or near-total thyroidectomy and RAI remnant ablation after one year follow-up
5. Recurrence rate after one year follow-up
6. AEs related to L-T4 (or thyroid tablet)treatment
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02870569 -
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01876784 -
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
Completed |
NCT04971473 -
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
|
Phase 3 | |
Recruiting |
NCT04964284 -
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
Recruiting |
NCT05078853 -
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
|
||
Active, not recruiting |
NCT03690388 -
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
|
Phase 3 | |
Recruiting |
NCT01700699 -
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
|
N/A | |
Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
Recruiting |
NCT04563780 -
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
|
||
Completed |
NCT03191643 -
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
|
N/A | |
Completed |
NCT02278198 -
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
|
Phase 1 | |
Active, not recruiting |
NCT04447183 -
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
|
Phase 2 | |
Active, not recruiting |
NCT01263951 -
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
|
Phase 2 | |
Active, not recruiting |
NCT04940052 -
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
|
Phase 3 | |
Recruiting |
NCT04880798 -
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
|
N/A | |
Recruiting |
NCT05789667 -
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
|
||
Recruiting |
NCT05660954 -
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
|
Phase 2 | |
Completed |
NCT00295763 -
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
|
Phase 3 | |
Recruiting |
NCT04321954 -
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
|
Phase 2 |